IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1001-1025 out of 1232.

<< < 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 > >>

Public Release: 25-Nov-2013
Annals of Internal Medicine
Nov. 26, 2013, Annals of Internal Medicine tip sheet
The United States Preventive Services Task Force found insufficient evidence to recommend for or against screening for oral cancer by primary care physicians in asymptomatic adults, according to an article published in Annals of Internal Medicine.

Contact: Megan Hanks
mhanks@acponline.org
215-351-2656
American College of Physicians

Public Release: 25-Nov-2013
Journal of Clinical Investigation
Predicting nasopharyngeal carcinoma patient response to radiation therapy
In this issue of the Journal of Clinical Investigation, Yu-Sun Chang and colleagues at Chang Gung University sought to find a way to predict which individual cases of NPC would be sensitive to radiation therapy.
Ministry of Education -- Taiwan, Chang Gung Memorial Hospital

Contact: Corinne Williams
press_releases@the-jci.org
Journal of Clinical Investigation

Public Release: 25-Nov-2013
Journal of Clinical Investigation
JCI early table of contents for Nov. 25, 2013
This release contains summaries, links to PDFs, and contact information for the following newsworthy papers to be published online, Nov. 25, 2013, in the JCI: Predicting nasopharyngeal carcinoma patient response to radiation therapy; Circadian clock proteins maintain neuronal cell function; Identifying targets of autoantibodies; Balancing T cell populations; Identification of a genetic mutation associated with steroid-resistant nephritic syndrome; Insights into type 2B von Willebrand disease, and more.

Contact: Corinne Williams
press_releases@the-jci.org
Journal of Clinical Investigation

Public Release: 25-Nov-2013
Developmental Cell
Dysfunctional mitochondria may underlie resistance to radiation therapy
The resistance of some cancers to the cell-killing effects of radiation therapy may be due to abnormalities in the mitochondria -- the cellular structures responsible for generating energy, according to an international team of researchers. Their findings are published in the Nov. 25 issue of Developmental Cell.
National Institutes of Health, Leukemia & Lymphoma Society, Natural Sciences and Engineering Research Council of Canada, Spanish Ministry

Contact: Sharon Parmet
sparmet@uic.edu
312-413-2695
University of Illinois at Chicago

Public Release: 25-Nov-2013
Journal of Experimental Medicine
Killer cocktail fights brain cancer
A novel immune-boosting drug combination eradicates an aggressive form of brain cancer in mice, according to a study in the Journal of Experimental Medicine.
Swiss National Science Foundation, European Union

Contact: Rita Sullivan King
news@rupress.org
212-327-8603
Rockefeller University Press

Public Release: 25-Nov-2013
Cancer
Certain symptom clusters experienced after surgery for esophageal cancer predict poor prognosis
A new study has found that several months after surgery for esophageal cancer, different symptoms cluster together in different types of patients. In addition, patients with certain symptom clusters have an increased risk of dying from their disease. The findings are published early online in CANCER, a peer-reviewed journal of the American Cancer Society.

Contact: Amy Molnar
sciencenewsroom@wiley.com
201-748-8844
Wiley

Public Release: 25-Nov-2013
Proceedings of the National Academy of Sciences
Using microRNA fit to a T (cell)
Researchers at the University of California, San Diego School of Medicine have successfully targeted T lymphocytes -- which play a central role in the body's immune response -- with another type of white blood cell engineered to synthesize and deliver bits of non-coding RNA or microRNA.
National Institutes of Health

Contact: Scott LaFee
slafee@ucsd.edu
619-543-6163
University of California - San Diego

Public Release: 25-Nov-2013
JAMA Internal Medicine
Cervical cancer screening overused in some groups of women
For the past 10 years, clinicians throughout the United States have been performing unnecessary Pap tests for cervical cancer screening in certain groups of women, according to a researcher from Huntsman Cancer Institute at the University of Utah.

Contact: Jill Woods
801-585-5321
University of Utah Health Sciences

Public Release: 25-Nov-2013
Journal of Clinical Oncology
Nurse navigators help cancer patients cope early in care
When Group Health patients received support from a nurse navigator, or advocate, soon after a cancer diagnosis, they had better experiences and fewer problems with their care -- particularly in health information, care coordination, and psychological and social care -- according to a randomized controlled trial in the Journal of Clinical Oncology.
NIH/National Cancer Institute

Contact: Rebecca Hughes
hughes.r@ghc.org
206-287-2055
Group Health Research Institute

Public Release: 23-Nov-2013
4th Quadrennial World Federation of Neuro-Oncology
Update: 50 percent of patients in Cedars-Sinai brain cancer study alive after 5 years
Eight of 16 patients participating in a study of an experimental immune system therapy directed against the most aggressive malignant brain tumors -- glioblastoma multiforme -- survived longer than five years after diagnosis, according to Cedars-Sinai researchers, who presented findings Nov. 23 at the Fourth Quadrennial Meeting of the World Federation of Neuro-Oncology.
IMUC, Ltd.

Contact: Sandy Van
sandy@prpacific.com
808-526-1708
Cedars-Sinai Medical Center

Public Release: 22-Nov-2013
Journal of Cancer
LSUHSC research finds combo of plant nutrients kills breast cancer cells
A study led by Madhwa Raj, Ph.D., Research Professor in Obstetrics and Gynecology at LSU Health Sciences Center New Orleans and its Stanley S. Scott Cancer Center, has found that a super cocktail of six natural compounds in vegetables, fruits, spices and plant roots killed 100 percent of sample breast cancer cells without toxic side effects on normal cells.

Contact: Leslie Capo
lcapo@lsuhsc.edu
504-568-4806
Louisiana State University Health Sciences Center

Public Release: 22-Nov-2013
Cancer Epidemiology, Biomarkers & Prevention
Sugar-sweetened beverage consumption increases endometrial cancer risk
Postmenopausal women who consumed sugar-sweetened beverages were more likely to develop the most common type of endometrial cancer compared with women who did not drink sugar-sweetened beverages, according to a study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.
NIH/National Cancer Institute

Contact: Jeremy Moore
jeremy.moore@aacr.org
215-446-7109
American Association for Cancer Research

Public Release: 22-Nov-2013
Science
Chemotherapy: When our intestinal bacteria provide reinforcement
Research jointly conducted by investigators at Institut Gustave Roussy, Inserm, Institut Pasteur and French National Agronomic Research Institute has led to a rather surprising discovery on the manner in which cancer chemotherapy treatments act more effectively with the help of the intestinal flora (also known as the intestinal microbiota).

Contact: Laurence Zitvogel
laurence.zitvogel@igr.fr
INSERM (Institut national de la santé et de la recherche médicale)

Public Release: 22-Nov-2013
American Journal of Hematology
Study finds link between allergies and increased risk of blood cancers in women
A team of scientists looking into the interplay of the immune system and cancer have found a link between a history of airborne allergies -- in particular to plants, grass and trees -- with risk of blood cancers in women.
NIH/National Cancer Institute

Contact: Kristen Woodward
media@fredhutch.org
206-667-2210
Fred Hutchinson Cancer Research Center

Public Release: 22-Nov-2013
Nature Immunology
Paths not taken: Notch signaling pathway keeps immature T cells on the right track
One protein called Notch, which has well-known roles in the development of multiple tissues, plays an essential role in triggering T-cell development. Notch signaling induces expression of genes that promote the maturation of T cells and discourage alternative cell fates. Deficiency of the Notch target gene Hes1 in blood stem cells results in extremely low T-cell numbers, and could shed light on how normal cells are transformed in the context of cancer.
NIH/National Institute of Allergy and Infectious Disease, NIH/National Cancer Institute, NIH/National Institute of General Medical Sciences

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine

Public Release: 21-Nov-2013
Cell
Scientists show how cells protect their DNA from catastrophic damage
Researchers at the University of Copenhagen have unveiled a profound biological process that explains how DNA can be damaged during genome replication. In addition, the scientists developed a new analytical tool to measure the cell's response to chemotherapy, which could have an important impact on future cancer therapy. The results are now published in the scientific journal Cell.

Contact: Luis Ignacio Toledo
luis.toledo@cpr.ku.dk
45-31-10-19-66
University of Copenhagen

Public Release: 21-Nov-2013
Journal of Wound Ostomy and Continence Nursing
Rutgers-Camden nursing scholar develops tool for ostomy care
Nurses caring for ostomy patients will now be equipped with an essential new tool developed by a Rutgers-Camden scholar that provides them with the first comprehensive guide to optimize ostomy management and enhance patient safety.

Contact: Ed Moorhouse
ejmoor@camden.rutgers.edu
856-225-6759
Rutgers University

Public Release: 21-Nov-2013
Cell
2 human proteins found to affect how 'jumping gene' gets around
Using a new method to catch elusive "jumping genes" in the act, researchers have found two human proteins that are used by one type of DNA to replicate itself and move from place to place. The discovery, described in the Nov. 21 issue of Cell, breaks new ground in understanding the arms race between a jumping gene and cells working to limit the risk posed by such volatile bits of DNA.
NIH/National Institute of General Medical Sciences

Contact: Shawna Williams
shawna@jhmi.edu
410-955-8236
Johns Hopkins Medicine

Public Release: 21-Nov-2013
Molecular Cell
Targets of anticancer drugs have broader functions than what their name suggests
Drugs that inhibit the activity of enzymes called histone deacetylases (HDACs) are being widely developed for treating cancer and other diseases, with two already on the market. Researchers show that a major HDAC still functions in mice even when its enzyme activity is abolished, suggesting that the beneficial effects of HDAC inhibitors may not actually be through inhibiting HDAC activity, and thus warranting the reassessment of the molecular targets of this class of drugs.
NIH/National Institute of Diabetes and Digestive and Kidney Diseases

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine

Public Release: 21-Nov-2013
Journal of Cell Science
A study on cell migration provides insights into the movement of cancer cells
The migration of groups of cells in order to form tissues is common during the development of an organism. Discovering how these multiple movements are achieved is not only crucial to understand the basic principles of development but provides new information and insights for further research into processes associated with the spread of cancer.

Contact: Sònia Armengou
armengou@irbbarcelona.org
34-934-037-255
Institute for Research in Biomedicine (IRB Barcelona)

Public Release: 21-Nov-2013
Cancer Discovery
SU2C researcher identifies potential treatment option for melanoma
Stand Up To Cancer, the charitable initiative supporting ground-breaking research to accelerate new cancer treatments, announces that the Allan H. (Bud) and Sue Selig Stand Up To Cancer Melanoma Innovative Research Grant Recipient Roger S. Lo, M.D., Ph.D., (Jonsson Comprehensive Cancer Center, UCLA) has published two studies in Cancer Discovery which indicate that treatment using combinatory therapy may be effective in suppressing drug resistance in the treatment of melanoma.
Stand Up To Cancer

Contact: Jane E. Rubinstein
jrubinstein@rubenstein.com
212-843-8287
Rubenstein Associates, Inc.

Public Release: 21-Nov-2013
Biomacromolecules
Research paves path for hybrid nano-materials that could replace human tissue or today's pills
A team of researchers has uncovered critical information that could help scientists understand how protein polymers interact with other self-assembling biopolymers. The research helps explain naturally occurring nano-material within cells and could one day lead to engineered bio-composites for drug delivery, artificial tissue, bio-sensing, or cancer diagnosis. The collaborative research was centered in the Polytechnic Institute of New York University Montclare Lab for Protein Engineering and Molecular Design.
National Science Foundation, Society of Plastics Engineers, Swiss National Science Foundation, Adolphe-Merkle Foundation

Contact: Kathleen Hamilton
hamilton@poly.edu
718-260-3792
New York University Polytechnic School of Engineering

Public Release: 21-Nov-2013
Epigenetics
A hallmark for the development of testicular tumors found in the aberrant regulation of small non-coding RNA
Researchers from the Bellvitge Biomedical Research Institute in Barcelona, Spain, have studied the role of a peculiar class of small non-coding RNAs that are mainly expressed in the human male germline.

Contact: Andrew Thompson
andrew@landesbioscience.com
Landes Bioscience

Public Release: 21-Nov-2013
Science Translational Medicine
UCLA researchers' new technique improves accuracy, ease of cancer diagnosis
A team of researchers from UCLA and Harvard University have demonstrated a technique, deformability cytometry, that measures the physical properties of individual cells and can diagnose cancer from body fluids with very high accuracy.

Contact: Matthew Chin
mchin@support.ucla.edu
310-206-0680
University of California - Los Angeles

Public Release: 21-Nov-2013
Cancer Discovery
UCLA research could enhance treatments for drug-resistant melanoma
Drugs called BRAF inhibitors shrink most melanoma tumors quickly. Despite good responses, melanoma tumors do not shrink away completely. Left-behind cancer cells allow tumors to grow back drug resistant. Using multiple drugs that simultaneously target the different tumor resistance mechanisms may prevent drug resistance and tumor regrowth.

Contact: Shaun Mason
smason@mednet.ucla.edu
310-206-2805
University of California - Los Angeles

Showing releases 1001-1025 out of 1232.

<< < 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 > >>

  Search News Releases

     

 

 

EurekAlert!